Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas | Zendy

Paolo G. Casali | Zendy; Axel Le Cesne | Zendy; A. Poveda Velasco | Zendy; Dusan Kotasek | Zendy; Piotr Rutkowski | Zendy; Peter Hohenberger | Zendy; Elena Fumagalli | Zendy; Ian Judson | Zendy; Antoîne Italiano | Zendy; Hans Gelderblom | Zendy; Antoine Adenis | Zendy; Jörg T. Hartmann | Zendy; Florence Duffaud | Zendy; David Goldstein | Zendy; Javier MartínBroto | Zendy; Alessandro Gronchi | Zendy; Angelo Paolo Dei Tos | Zendy; Sandrine Marréaud | Zendy; Winette T.A. van der Graaf | Zendy; John Zalcberg | Zendy; Saskia Litière | Zendy; JeanYves Blay | Zendy

Open Access

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas

Author(s) -

Paolo G. Casali,

Axel Le Cesne,

A. Poveda Velasco,

Dusan Kotasek,

Piotr Rutkowski,

Peter Hohenberger,

Elena Fumagalli,

Ian Judson,

Antoîne Italiano,

Hans Gelderblom,

Antoine Adenis,

Jörg T. Hartmann,

Florence Duffaud,

David Goldstein,

Javier MartínBroto,

Alessandro Gronchi,

Angelo Paolo Dei Tos,

Sandrine Marréaud,

Winette T.A. van der Graaf,

John Zalcberg,

Saskia Litière,

JeanYves Blay

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2015.62.4304

Subject(s) - medicine , gist , imatinib , hazard ratio , interim analysis , clinical endpoint , imatinib mesylate , tyrosine kinase inhibitor , adjuvant therapy , oncology , surgery , confidence interval , randomized controlled trial , cancer , gastroenterology , stromal cell , myeloid leukemia

In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog